semaglutide vs tirzepatide
updated
semaglutide (tier S) vs tirzepatide (tier S): what each is, half-life and source counts side by side.
the difference
checked
SURMOUNT-5 compared maximum tolerated weekly tirzepatide and semaglutide doses for 72 weeks in 751 adults with obesity and no diabetes. Mean weight change was -20.2 percent versus -13.7 percent. The open-label group result does not prescribe an individual choice.
- reptides claim check: tirzepatide vs semaglutide for weight loss
- Aronne LJ et al. N Engl J Med 2025, SURMOUNT-5 (PMID 40353578)
in type 2 diabetes, SURPASS-2 randomized 1,879 people to tirzepatide or semaglutide for 40 weeks, and every tirzepatide dose tested lowered HbA1c more than semaglutide.
tirzepatide is FDA-approved as Mounjaro for type 2 diabetes, including lowering cardiovascular risk in adults at high risk, and as Zepbound for long-term weight reduction and for obstructive sleep apnea in adults with obesity.
- Mounjaro prescribing information, DailyMed (revised 8/2026)
- Zepbound prescribing information, DailyMed (revised 8/2026)
semaglutide is FDA-approved as Ozempic and Rybelsus for type 2 diabetes, including lowering cardiovascular risk in adults with established cardiovascular disease (Ozempic injection) or at high risk (Rybelsus tablets), and as Wegovy for long-term weight reduction and to lower cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.
- Ozempic injection prescribing information, DailyMed (revised 5/2026)
- Rybelsus and Ozempic tablets prescribing information, DailyMed (revised 1/2026)
- Wegovy prescribing information, DailyMed (revised 6/2026)
semaglutide · tier S
A GLP-1 receptor agonist with current US injection and oral products for distinct labeled uses.
tier rationale
The S tier reflects large randomized trials showing weight-loss, cardiovascular, and kidney benefits in the studied populations, plus positive biopsy outcomes in a planned phase 3 liver-disease interim analysis.
tirzepatide · tier S
A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.
tier rationale
Tirzepatide is in S tier because large randomized trials have shown weight loss, improved blood-sugar control and reduced sleep-apnea severity. Zepbound and Mounjaro have US approvals for these uses.
at a glance
| semaglutide | tirzepatide | |
|---|---|---|
| tier | S | S |
| category | weight loss | weight loss |
| sources | 16 | 20 |
| claims evaluated | n/a | n/a |
| half-life | ~1 week | ~5 days |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.